FDA Dings Sesen Bio for Misconduct by Study Investigator

By PacConAdmin | October 28, 2021

Sesen Bio received an FDA warning letter Oct. 27, knocking the company over a 4-year-old personnel issue that came to light in a recent biologics license application (BLA) review of Vicineum for treatment of bladder cancer.
Source: Drug Industry Daily

Posted in Drug Industry Daily